At ObesityWeek on Sunday, Viking Therapeutics unveiled early data from the first-in-human study of its investigational oral obesity drug VK2735, touting strong weight loss in healthy adults and an encouraging safety profile.
34% for Semaglutide) Eli Lilly struggles to meet global Tirzepatide demand, with projected shortages into 2026
Many healthcare professionals recommend aiming for a higher protein intake during weight loss, but the right amount is individual
No GLP-2 medication is approved for the indications GLP-1 medications cover
Unlike currently approved therapies such as semaglutide and tirzepatide, retatrutide acts on three metabolic pathways, leading many obesity medicine experts to view it as a potential next-generation treatment for obesity and related metabolic conditions
Israel has lost one of its greatest friends